Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
Purpose: We evaluated whether 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) could be used as imaging biomarkers of platinum resensitization in ovarian cancer.Procedures: Paired platinum-sensitive and platinum-res...
| Published in: | Molecular Imaging & Biology Vol. 14; no. 6; pp. 753 - 762 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | research Journal Article |
| Published: |
Springer Nature
Dec2012
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104383961&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104383961 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15361632 KJU jtl: Molecular Imaging & Biology issn: 15361632 maglogo: N pubinfo: dt: Dec2012 vid: 14 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104383961 104383961 NLM22484552 2011754999 10.1007/s11307-012-0554-2 NLM22484552 104383961 ppf: 753 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer. aug: au: Perumal M Stronach EA Gabra H Aboagye EO Perumal, Meg Stronach, Euan A Gabra, Hani Aboagye, Eric O affil: Comprehensive Cancer Imaging Centre, Department of Cancer & Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, 240 MRC Cyclotron Building, Du Cane Road, London, W12 0NN, UK sug: subj: Deoxyribonucleosides Diagnostic Use Drug Resistance, Neoplasm Fludeoxyglucose F 18 Diagnostic Use Ovarian Neoplasms Radiography Platinum Therapeutic Use Tomography, Emission-Computed Tumor Markers, Biological Metabolism Animal Studies Blotting, Western Cells Deoxyribonucleosides Pharmacokinetics Female Fludeoxyglucose F 18 Pharmacokinetics Mice Ovarian Neoplasms Drug Therapy Platinum Pharmacodynamics Sulfonylurea Compounds Time Factors Treatment Outcomes Female ab: Purpose: We evaluated whether 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) could be used as imaging biomarkers of platinum resensitization in ovarian cancer.Procedures: Paired platinum-sensitive and platinum-resistant ovarian cancer cells from the same patient, PEO1 and PEO4, grown as tumor xenografts in nude mice, were assessed by PET.Results: The AKT inhibitor, API-2, resensitized platinum-resistant PEO4 tumors to cisplatin, leading to a markedly lower Ki67 labeling index (p ≤ 0.006, n = 6 per group). [(18)F]FDG-PET and [(18)F]FLT-PET imaging variables were lower after combination treatment compared with vehicle treatment (p ≤ 0.006, n = 6 per group). No changes were seen with either drug alone. PRAS40 phosphorylation status was a sensitive biochemical marker of pathway inhibition, whereas reductions thymidine kinase 1 expression defined the [(18)F]FLT response.Conclusions: Therapeutic inhibition of AKT activation in acquired platinum-resistant disease can be imaged noninvasively by [(18)F]FDG-PET and [(18)F]FLT-PET warranting further assessment. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|